Evidence map›Paper›PMID 36048326›Full record

ReviewClinical reviews in allergy & immunology2022

Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review.

Benjamin Greiner, Savannah Nicks, Michael Adame, Jennifer McCracken

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Benjamin GreinerDepartment of Internal Medicine, Medical Branch, University of Texas, 301 University Blvd, Galveston, TX, USA. bhgreine@utmb.edu.ORCID http://orcid.org/0000-0001-7604-2539
Savannah NicksDepartment of Otolaryngology, McLaren Oakland Hospital, Pontiac, MI, USA.
Michael AdameDepartment of Internal Medicine, Medical Branch, University of Texas, 301 University Blvd, Galveston, TX, USA.
Jennifer McCrackenDepartment of Internal Medicine, Medical Branch, University of Texas, 301 University Blvd, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · US

Funding

Physician-Scientist Training in Emerging Infectious DiseasesT32AI155385 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MELBY, PETER C., PAESSLER, SLOBODAN · 2021 to 2025
$775k
NIAID NIH HHS T32 AI155385
6 · The paper itself

Abstract

Chronic spontaneous urticaria (CSU) is characterized by recurring wheals that last 6 weeks or longer without an identifiable cause. The estimated point prevalence of CSU worldwide is 1%. Furthermore, it has a significant impact on quality of life in both adults and pediatric patients and their families. Although it is most often a self-limited disease, some patients have urticaria refractory to first-line treatment: second-generation H1 antihistamines. In these patients, the use of targeted monoclonal antibodies is necessary. While omalizumab is the only Food and Drug Administration-approved monoclonal antibody for CSU, others, including ligelizumab, dupilumab, benralizumab, and several orally administered Bruton's tyrosine kinase inhibitors, are also promising therapeutics for reducing the morbidity of CSU. Novel therapies, among others discussed here, are rapidly being developed with new trials and therapeutics being released nearly monthly. Thus, we performed a scoping literature review of randomized controlled trials studying targeted therapies for CSU. We also discuss the pathophysiology, diagnosis, prognosis, and future research directions in CSU.

Indexed as

Chronic UrticariaUrticariaAdultAntibodies, MonoclonalChildHumansOmalizumabQuality of LifeUnited StatesAntibodies, MonoclonalOmalizumabChronic idiopathic urticariaChronic spontaneous urticariaManagementSystematic reviewTargeted therapy

Identifiers

PMID36048326
OpenAlexW4294123386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.